Skip to content
2000
Volume 14, Issue 12
  • ISSN: 1389-4501
  • E-ISSN: 1873-5592

Abstract

Inflammatory bowel diseases (IBD) are considered barrier diseases. After misleading initial results, the pathogenic importance of a disturbed mucosa is now widely accepted, largely because a certain percentage of first-degree relatives of patients with IBD do have permeability alterations, as assessed by oral markers. In the presence of a normal appearing gut mucosa, functional alterations of the highly dynamic inter-enterocyte tight junctions have to be considered to be responsible for the observed alterations. Indeed, various alterations of the transmembrane and intracytoplasmic proteins have been reported in IBD. An important therapeutic goal is to maintain disease remission by preservation of the correct organization of these complexes. Of the potential therapeutic approaches, the various anti-TNF agents are the best-studied agents, but other treatments may tighten the gut through as yet unknown mechanisms.

Loading

Article metrics loading...

/content/journals/cdt/10.2174/1389450111314120011
2013-11-01
2025-05-20
Loading full text...

Full text loading...

/content/journals/cdt/10.2174/1389450111314120011
Loading

  • Article Type:
    Research Article
Keyword(s): Barrier function; claudins; IBD; intestinal permeability; MLCK; occludin; tight junctions; TNF-α
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test